Cancer
01 Jan 2013
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities
Advanced colorectal cancer. To establish the dose-limiting toxicities and maximum-tolerated dose of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in combination with FOLFIRI, a standard regimen of irinotecan, leucovorin, and infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer. Official Title Conditions Study Type…
Cancer
01 Jan 2013
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
RATIONALE: Sulindac may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Hormone therapy using tamoxifen may fight cancer by blocking the uptake of estrogen. Combining sulindac with tamoxifen may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining…
Cancer
01 Jan 2013
Treatment of non-Hodgkin’s lymphoma with rituximab plus CHOP chemotherapy: 9-year follow-up
The objective of the study was to present long-term follow-up data with updated time to disease progression (TTP) and duration of response (DR) from a multicenter, phase II trial of R-CHOP combination therapy in 40 patients with CD20+, B-cell NHL. Primary endpoints: ORR, PR rate and CR rate; secondary endpoints:…
Cancer
01 Jan 2013
Anti-angiogenesis Agent AG-013736 in Patients with Metastatic Melanoma
This is a Phase 2 study being conducted at multiple centers in the United States. Patients having melanoma that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that has been treated with no more than 1 prior treatment for metastatic…
Cancer
01 Jan 2013
Study of SU011248 in Patients with Neuroendocrine Tumors
The primary objective of the study is to determine the efficacy and safety of SU011248 as a treatment for patients with advanced unresectable neuroendocrine tumor; however, CURRENTLY ONLY RECRUITING FOR PATIENTS SPECIFICALLY WITH PANCREATIC ISLET CELL TUMORS. Official Title Phase II Study of SU011248 in Patients with Neuroendocrine Tumors; however,…
Cancer
01 Jan 2013
Study of SU011248 in Patients with Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel. Official Title A Phase 2 Efficacy and Safety Study of SU011248 in Patients with Metastatic Non-Small Cell Lung…
Cancer
01 Jan 2013
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients. PURPOSE: Randomized clinical trial to study the effectiveness of celecoxib in managing pain, weight loss, and weakness in patients with advanced cancer. Official Title…
Cancer
01 Jan 2013
FOLFOX4 in Patients with Normal and Abnormal Renal Function
This trial is a phase II study of patients with advanced gastrointestinal (GI) malignancies who will be assigned to one of 4 cohorts (normal, mild dysfunction, moderate dysfunction and severe renal dysfunction) based on their baseline measured creatinine clearance then treated with FOLFOX4. Standard bone marrow and liver function…
Cancer
01 Jan 2013
Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer
In this Phase IIIb, randomized, double-blind, maintenance study, 300 subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) (Stage IIIB {T4-pleural effusion} and IV) who have SD or objective tumor response immediately following the completion of 4-6 cycles of front line, platinum-based, doublet chemotherapy will be randomized in a…
